Invention Grant
- Patent Title: Selective HDAC1 and HDAC2 inhibitors
-
Application No.: US15677581Application Date: 2017-08-15
-
Publication No.: US09957259B2Publication Date: 2018-05-01
- Inventor: John H. van Duzer , Ralph Mazitschek
- Applicant: REGENACY PHARMACEUTICALS, LLC
- Applicant Address: US MA Boston
- Assignee: REGENACY PHARMACEUTICALS, LLC
- Current Assignee: REGENACY PHARMACEUTICALS, LLC
- Current Assignee Address: US MA Boston
- Agency: Lathrop Gage LLP
- Agent Brian C. Trinque
- Main IPC: C07D409/12
- IPC: C07D409/12 ; C07D209/08 ; C07D209/34 ; C07D215/48 ; C07D231/56 ; C07D333/20 ; C07D401/12 ; C07D471/04 ; A61K31/4709 ; A61K31/4045 ; C07D215/54 ; A61K31/496 ; A61K31/5377 ; A61K31/498
Abstract:
Provided herein are compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1 and/or HDAC2. Such diseases include cancer, sickle-cell anemia, beta-thalassemia, and HIV.
Public/Granted literature
- US20180030040A1 SELECTIVE HDAC1 AND HDAC2 INHIBITORS Public/Granted day:2018-02-01
Information query
